Due to those inconsistent conclusions above, we herein aimed to perform a meta-analysis to explore the prognostic role of T790M mutation in advanced NSCLC patients treated with EGFR-TKIs that developed drug resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.